Cytori Therapeutics is set to gain cancer drugs and a liposomal nanoparticle technology platform through the acquisition of Azaya Therapeutics. The lead drug is a formulation of doxorubicin, the ...
Cytori Therapeutics said today it plans to acquire the liposomal nanoparticle technology platform of Azaya Therapeutics for up to $170 million, in a deal designed to expand and complement the buyer’s ...
The acquisition of two partner-ready nanoparticle cancer candidates developed by Azaya Therapeutics Inc. and an associated nanotech platform could yield potential near-term revenue for Cytori ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback